Evotec and Apeiron Biologics have entered into a discovery project on the Cbl-b target for an anti-tumor immune therapy. Financial terms were not disclosed. Evotec will apply its technologies in cellular assay development and ultra-high throughput screening (uHTS) to identify biologically active molecules from its corporate library that interact with Cbl-b. Cbl-b plays a role in both the adaptive and the innate immune system and its manipulation can potentially enhance anti-tumor activities for...